SULT1B1

Summary

SULT1B1 (sulfotransferase family 1B member 1, HGNC:17845) is a protein-coding gene on chromosome 4q13.3, encoding Sulfotransferase 1B1 (O43704). Sulfotransferase that utilizes 3’-phospho-5’-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of dopamine, small phenols such as 1-naphthol and p-nitrophenol and thyroid hormones, including 3,3’-diiodothyronine, triidothyronine (T3) and reverse trii….

Sulfotransferase enzymes catalyze the sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds. These cytosolic enzymes are different in their tissue distributions and substrate specificities. The gene structure (number and length of exons) is similar among family members. However, the total genomic length of this gene is greater than that of other SULT1 genes.

Source: NCBI Gene 27284 — RefSeq curated summary.

At a glance

• Gene–disease (curated): schizophrenia (No Known Disease Relationship, GenCC)
• GWAS associations: 4
• Clinical variants (ClinVar): 44 total
• Druggable target: yes
• MANE Select transcript: NM_014465

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17845
Approved symbol	SULT1B1
Name	sulfotransferase family 1B member 1
Location	4q13.3
Locus type	gene with protein product
Status	Approved
Aliases	ST1B2
Ensembl gene	ENSG00000173597
Ensembl biotype	protein_coding
OMIM	608436
Entrez	27284

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000310613, ENST00000510821, ENST00000512870, ENST00000868536, ENST00000868537, ENST00000868538, ENST00000868539

RefSeq mRNA: 1 — MANE Select: NM_014465 NM_014465

CCDS: CCDS3530

Canonical transcript exons

ENST00000310613 — 8 exons

Exon	Start	End
ENSE00001180373	69730501	69730681
ENSE00001180380	69733413	69733507
ENSE00001180385	69734138	69734264
ENSE00001180389	69749721	69749818
ENSE00001180398	69760459	69760620
ENSE00001180407	69755070	69755261
ENSE00001239171	69721167	69727200
ENSE00003788576	69754670	69754798

Expression profiles

Bgee: expression breadth ubiquitous, 161 present calls, max score 95.96.

FANTOM5 (CAGE): breadth broad, TPM avg 4.8913 / max 566.6373, expressed in 486 samples.

FANTOM5 promoters (13 alternative TSS)

Promoter ID	TPM avg	Samples expressed
52374	1.8282	270
52377	1.1863	266
52383	0.5238	96
52382	0.2984	76
52375	0.2914	107
52379	0.2575	71
52378	0.1535	64
52376	0.1490	64
52380	0.0911	25
52373	0.0537	27

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
rectum	UBERON:0001052	95.96	gold quality
mucosa of transverse colon	UBERON:0004991	92.61	gold quality
jejunal mucosa	UBERON:0000399	92.56	gold quality
duodenum	UBERON:0002114	91.73	gold quality
monocyte	CL:0000576	86.87	gold quality
colonic epithelium	UBERON:0000397	86.77	gold quality
mononuclear cell	CL:0000842	86.61	gold quality
colonic mucosa	UBERON:0000317	86.57	gold quality
leukocyte	CL:0000738	86.37	gold quality
transverse colon	UBERON:0001157	84.33	gold quality
mucosa of sigmoid colon	UBERON:0004993	83.98	gold quality
blood	UBERON:0000178	81.78	gold quality
ileal mucosa	UBERON:0000331	80.37	gold quality
small intestine	UBERON:0002108	80.22	gold quality
small intestine Peyer’s patch	UBERON:0003454	78.88	gold quality
right lobe of liver	UBERON:0001114	78.75	gold quality
right lung	UBERON:0002167	77.94	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.73	silver quality
vermiform appendix	UBERON:0001154	77.04	gold quality
intestine	UBERON:0000160	76.77	gold quality
liver	UBERON:0002107	76.55	gold quality
diaphragm	UBERON:0001103	76.22	gold quality
stomach	UBERON:0000945	75.51	gold quality
large intestine	UBERON:0000059	75.19	gold quality
body of stomach	UBERON:0001161	75.19	gold quality
granulocyte	CL:0000094	75.03	gold quality
caecum	UBERON:0001153	74.94	gold quality
spleen	UBERON:0002106	74.90	gold quality
colon	UBERON:0001155	74.53	gold quality
jejunum	UBERON:0002115	72.74	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9543	yes	971.87
E-ANND-3	yes	7.50
E-ENAD-20	no	85.93
E-MTAB-9067	no	4.30
E-GEOD-83139	no	3.90

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RORA

miRNA regulators (miRDB)

11 targeting SULT1B1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4422	99.72	72.07	2908
HSA-MIR-3942-3P	99.57	69.03	2854
HSA-MIR-4279	99.19	66.70	2437
HSA-MIR-5100	99.11	67.52	1098

Literature-anchored findings (GeneRIF, showing 4)

• linkage to SULT1E1 and a SULT1D1 pseudogene on chromosome 4 (PMID:11688987)
• crystal structures of two members of SULT1 family, SULT1B1 and SULT1C1, both in complex with the product of the PAPS cofactor, adenosine-3-5-diphosphate (PAP). (PMID:16804942)
• the intersubunit interactions of SULT1B1 as it relates to enzyme activity (PMID:27338799)
• (L145V) selectively expressed in African descendants exhibits altered kinetic properties (PMID:28084139)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	sult2st3	ENSDARG00000028367
mus_musculus	Sult1b1	ENSMUSG00000029269
rattus_norvegicus	Sult1b1	ENSRNOG00000001967
drosophila_melanogaster	St4	FBGN0033887
drosophila_melanogaster	St1	FBGN0034887
drosophila_melanogaster	St3	FBGN0265052

Paralogs (12): SULT2B1 (ENSG00000088002), SULT2A1 (ENSG00000105398), SULT1E1 (ENSG00000109193), SULT4A1 (ENSG00000130540), SULT6B1 (ENSG00000138068), SULT1C3 (ENSG00000196228), SULT1A1 (ENSG00000196502), SULT1A2 (ENSG00000197165), SULT1C4 (ENSG00000198075), SULT1C2 (ENSG00000198203), SULT1A4 (ENSG00000213648), SULT1A3 (ENSG00000261052)

Protein

Protein identifiers

Sulfotransferase 1B1 — O43704 (reviewed: O43704)

Alternative names: Sulfotransferase 1B2, Sulfotransferase family cytosolic 1B member 1, Thyroid hormone sulfotransferase

All UniProt accessions (3): O43704, D6RD70, D6RIA8

UniProt curated annotations — full annotation on UniProt →

Function. Sulfotransferase that utilizes 3’-phospho-5’-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of dopamine, small phenols such as 1-naphthol and p-nitrophenol and thyroid hormones, including 3,3’-diiodothyronine, triidothyronine (T3) and reverse triiodothyronine (rT3). May play a role in gut microbiota-host metabolic interaction. O-sulfonates 4-ethylphenol (4-EP), a dietary tyrosine-derived metabolite produced by gut bacteria. The product 4-EPS crosses the blood-brain barrier and may negatively regulate oligodendrocyte maturation and myelination, affecting the functional connectivity of different brain regions associated with the limbic system.

Subcellular location. Cytoplasm.

Tissue specificity. Highly expressed in the liver, peripheral blood leukocytes, colon (mucosal lining), small intestine (jejunum) and spleen. A lesser expression was observed in the lung, placenta and thymus.

Similarity. Belongs to the sulfotransferase 1 family.

RefSeq proteins (1): NP_055280* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000863	Sulfotransferase_dom	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF00685

Enzyme classification (BRENDA):

• EC 2.8.2.1 — aryl sulfotransferase (BRENDA: 19 organisms, 630 substrates, 215 inhibitors, 314 Km, 55 kcat entries)
• EC 2.8.2.2 — alcohol sulfotransferase (BRENDA: 13 organisms, 295 substrates, 100 inhibitors, 159 Km, 25 kcat entries)

Substrate kinetics (BRENDA)

180 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
DOPAMINE	0.0006–11.3	39
4-NITROPHENOL	0.0001–30.9	36
DEHYDROEPIANDROSTERONE	0.0006–0.0179	23
3’-PHOSPHOADENYLYLSULFATE	0.0003–0.51	17
ACETAMINOPHEN	0.43–4.5	14
MORPHINE	3.8–10	13
O-DESMETHYL TRAMADOL	0.27–0.8	13
TAPENTADOL	0.09–0.84	13
3’-PHOSPHOADENYLYL SULFATE	0.0008–0.024	12
ANDROSTERONE	0.0002–0.0096	11
DAIDZEIN	0.0005–0.407	8
GENISTEIN	0.0005–0.371	8
6-HYDROXYMELATONIN	0.018–0.065	6
3’-PHOSPHOADENYLYLSULFATE	0.0001–0.1	6
7-HYDROXYCOUMARIN	0.0005–0.003	4

Catalyzed reactions (Rhea), 7 shown:

• a phenol + 3’-phosphoadenylyl sulfate = an aryl sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:12164)
• 3,3’,5-triiodo-L-thyronine + 3’-phosphoadenylyl sulfate = 3,3’,5-triiodo-L-thyronine sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:67876)
• dopamine + 3’-phosphoadenylyl sulfate = dopamine 3-O-sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:67880)
• dopamine + 3’-phosphoadenylyl sulfate = dopamine 4-O-sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:67884)
• 3,3’,5’-triiodo-L-thyronine + 3’-phosphoadenylyl sulfate = 3,3’,5’-triiodo-L-thyronine sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:67888)
• 3,3’-diiodo-L-thyronine + 3’-phosphoadenylyl sulfate = 3,3’-diiodo-L-thyronine sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:67892)
• 4-ethylphenol + 3’-phosphoadenylyl sulfate = 4-ethylphenyl sulfate + adenosine 3’,5’-bisphosphate + H(+) (RHEA:70607)

UniProt features (42 total): helix 16, turn 8, binding site 7, strand 6, sequence conflict 2, chain 1, active site 1, sequence variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
3CKL	X-RAY DIFFRACTION	2
2Z5F	X-RAY DIFFRACTION	2.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43704-F1	97.88	0.97

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 109 (proton acceptor)

Ligand- & substrate-binding residues (7): 48–53; 107–109; 131; 139; 194; 228–233; 258–260

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-156584	Cytosolic sulfonation of small molecules
R-HSA-1430728	Metabolism
R-HSA-156580	Phase II - Conjugation of compounds
R-HSA-211859	Biological oxidations

MSigDB gene sets: 141 (showing top): GOBP_PHENOL_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_EPITHELIUM_DEVELOPMENT, HORIUCHI_WTAP_TARGETS_DN, REACTOME_BIOLOGICAL_OXIDATIONS, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_THYROID_HORMONE_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_SULFATION, LEE_LIVER_CANCER_CIPROFIBRATE_DN, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, chr4q13, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, CAIRO_HEPATOBLASTOMA_CLASSES_DN, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GOBP_ORGANIC_ACID_METABOLIC_PROCESS

GO Biological Process (9): ethanol catabolic process (GO:0006068), biogenic amine metabolic process (GO:0006576), xenobiotic metabolic process (GO:0006805), flavonoid metabolic process (GO:0009812), phenol-containing compound metabolic process (GO:0018958), epithelial cell differentiation (GO:0030855), thyroid hormone metabolic process (GO:0042403), 3’-phosphoadenosine 5’-phosphosulfate metabolic process (GO:0050427), sulfation (GO:0051923)

GO Molecular Function (4): aryl sulfotransferase activity (GO:0004062), sulfotransferase activity (GO:0008146), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Phase II - Conjugation of compounds	1
Biological oxidations	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metabolic process	3
sulfur compound metabolic process	2
cellular anatomical structure	2
ethanol metabolic process	1
primary alcohol catabolic process	1
amine metabolic process	1
cellular response to xenobiotic stimulus	1
cell differentiation	1
epithelium development	1
modified amino acid metabolic process	1
phenol-containing compound metabolic process	1
hormone metabolic process	1
purine ribonucleotide metabolic process	1
purine ribonucleoside bisphosphate metabolic process	1
oxoacid metabolic process	1
sulfotransferase activity	1
transferase activity, transferring sulphur-containing groups	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

940 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SULT1B1	CHST6	Q9GZX3	899
SULT1B1	NDST1	P52848	893
SULT1B1	PAPSS2	O95340	851
SULT1B1	HS3ST1	O14792	845
SULT1B1	PAPSS1	O43252	837
SULT1B1	HS3ST3A1	Q9Y663	834
SULT1B1	HS3ST3B1	Q9Y662	825
SULT1B1	NDST2	P52849	815
SULT1B1	CHST5	Q9GZS9	749
SULT1B1	CHST3	Q7LGC8	748
SULT1B1	HS3ST2	Q9Y278	731
SULT1B1	NDST3	O95803	729
SULT1B1	LUM	P51884	725
SULT1B1	CHST1	O43916	722
SULT1B1	SLC35A2	P78381	697

IntAct

34 interactions, top by confidence:

A	B	Type	Score
SULT2B1	SULT1B1	psi-mi:“MI:0915”(physical association)	0.810
SULT1B1	SULT2B1	psi-mi:“MI:0915”(physical association)	0.810
SULT1B1	SULT2A1	psi-mi:“MI:0915”(physical association)	0.720
SULT1B1	SDCBP	psi-mi:“MI:0915”(physical association)	0.560
TARS1	SULT1B1	psi-mi:“MI:0915”(physical association)	0.560
SULT1B1	UQCRC1	psi-mi:“MI:0915”(physical association)	0.560
VBP1	SULT1B1	psi-mi:“MI:0915”(physical association)	0.560
SULT1B1	POT1	psi-mi:“MI:0915”(physical association)	0.510
INSR	BLTP3B	psi-mi:“MI:0914”(association)	0.350
INSR	UBXN8	psi-mi:“MI:0914”(association)	0.350
INSR	ATOX1	psi-mi:“MI:0914”(association)	0.350
SULT1B1	POT1	psi-mi:“MI:0915”(physical association)	0.000
SULT2A1	SULT1B1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (10): SULT1B1 (Two-hybrid), SULT1B1 (Two-hybrid), SULT1B1 (Two-hybrid), SULT1B1 (Two-hybrid), SULT1B1 (Synthetic Lethality), SULT1B1 (Two-hybrid), SULT1B1 (Two-hybrid), SULT1B1 (Negative Genetic), SULT1B1 (Negative Genetic), SULT1B1 (Two-hybrid)

ESM2 similar proteins: A0A173GP47, A0A1L8HV70, A0A2K5X3B6, B2RVI8, F1QYJ6, G3V9R3, O00338, O43704, O46503, O75897, P0CC03, P15709, P17988, P19217, P22789, P27707, P46560, P48769, P49887, P49888, P49891, P50234, P50235, P50236, P50237, P52840, P52841, P52843, P52844, P52847, Q06520, Q3T0Y3, Q3UZZ6, Q5ZJM7, Q6IMI4, Q6IMI6, Q6PH37, Q6WG17, Q6WG18, Q7T2V2

Diamond homologs: A0A173GP47, A0A2K5X3B6, G3V9R3, O00338, O35400, O43704, O46503, O46640, O75897, P0DMM9, P0DMN0, P19217, P49887, P49888, P49891, P50236, P50237, P52839, P52840, P52842, P52844, P52847, P63046, P63047, Q29476, Q3T0Y3, Q3UZZ6, Q6IMI6, Q80VR3, Q8BGL3, Q8JG30, Q95JD5, Q9BR01, Q9C9D0, Q9D939, Q9FZ80, Q9QWG7, Q9WUW8, Q9WUW9, B2RVI8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1446 predictions. Top by Δscore:

Variant	Effect	Δscore
4:69730496:TTTAC:T	donor_loss	1.0000
4:69730497:TTAC:T	donor_loss	1.0000
4:69730498:TA:T	donor_loss	1.0000
4:69730499:ACC:A	donor_loss	1.0000
4:69730500:C:CT	donor_loss	1.0000
4:69730500:CCT:C	donor_gain	1.0000
4:69730679:ATT:A	acceptor_gain	1.0000
4:69730680:TT:T	acceptor_gain	1.0000
4:69730681:TC:T	acceptor_loss	1.0000
4:69730682:C:CC	acceptor_gain	1.0000
4:69730685:T:TC	acceptor_gain	1.0000
4:69730692:G:GC	acceptor_gain	1.0000
4:69730700:C:T	acceptor_gain	1.0000
4:69734133:CATA:C	donor_loss	1.0000
4:69734134:ATACC:A	donor_loss	1.0000
4:69734135:TACCT:T	donor_loss	1.0000
4:69734136:ACCT:A	donor_loss	1.0000
4:69734137:C:G	donor_loss	1.0000
4:69734261:TCAT:T	acceptor_gain	1.0000
4:69734262:CAT:C	acceptor_gain	1.0000
4:69734262:CATC:C	acceptor_gain	1.0000
4:69727044:C:CT	donor_gain	0.9900
4:69727045:T:TT	donor_gain	0.9900
4:69727051:CAAT:C	donor_gain	0.9900
4:69727060:A:AC	donor_gain	0.9900
4:69730677:GGATT:G	acceptor_gain	0.9900
4:69730678:GATT:G	acceptor_gain	0.9900
4:69730688:G:GC	acceptor_gain	0.9900
4:69730692:G:C	acceptor_gain	0.9900
4:69730700:C:CT	acceptor_gain	0.9900

AlphaMissense

1987 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:69755075:T:A	K48I	0.993
4:69730507:G:T	R258S	0.992
4:69730511:A:C	F256L	0.992
4:69730511:A:T	F256L	0.992
4:69730513:A:G	F256L	0.992
4:69755074:T:A	K48N	0.991
4:69755074:T:G	K48N	0.991
4:69734211:A:C	F143L	0.990
4:69734211:A:T	F143L	0.990
4:69734213:A:G	F143L	0.990
4:69734238:C:A	K134N	0.989
4:69734238:C:G	K134N	0.989
4:69730506:C:G	R258P	0.988
4:69754798:C:A	G50V	0.988
4:69733493:A:G	W173R	0.987
4:69733493:A:T	W173R	0.987
4:69734249:G:T	R131S	0.986
4:69734248:C:G	R131P	0.984
4:69727186:A:G	W265R	0.982
4:69727186:A:T	W265R	0.982
4:69749771:G:C	H109D	0.982
4:69754798:C:T	G50D	0.982
4:69734151:G:C	F163L	0.981
4:69734151:G:T	F163L	0.981
4:69734153:A:G	F163L	0.981
4:69734237:C:G	D135H	0.980
4:69749785:C:G	R104P	0.980
4:69754790:A:G	W53R	0.979
4:69754790:A:T	W53R	0.979
4:69755100:C:G	D40H	0.979

dbSNP variants (sampled 300 via entrez): RS1000159891 (4:69752056 A>G), RS1000177292 (4:69728028 C>T), RS1000327752 (4:69760525 G>C), RS1000367502 (4:69723264 A>G), RS1000438930 (4:69730985 G>C), RS1000458916 (4:69754375 T>C,G), RS1000592202 (4:69721932 T>C), RS1000695652 (4:69759058 C>T), RS1000760250 (4:69742529 A>C), RS1000762084 (4:69753459 A>G), RS1000800655 (4:69723089 T>G), RS1000832130 (4:69726490 G>A), RS1000885891 (4:69726739 A>C), RS1000920673 (4:69747762 C>T), RS1000972352 (4:69747228 G>A)

Disease associations

OMIM: gene MIM:608436 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
schizophrenia	No Known Disease Relationship	Unknown

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004294_5	Nicotine dependence	4.000000e-06
GCST006462_25	Uterine fibroids	6.000000e-13
GCST009158_40	Uterine fibroids	4.000000e-14
GCST011947_28	White matter hyperintensity volume	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005665	white matter hyperintensity measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1743294 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

61 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, increases methylation, decreases expression	4
bisphenol A	decreases expression, increases metabolic processing, affects cotreatment, increases methylation	3
Aflatoxin B1	increases expression, decreases expression	3
sodium arsenite	decreases expression	2
perfluorooctanoic acid	increases expression	2
4-nitrophenol	affects binding, decreases reaction, increases metabolic processing	2
perfluorooctane sulfonic acid	increases expression, decreases expression	2
Cyclosporine	decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	increases expression	1
perfluorodecanesulfonic acid	increases expression	1
2,4-dichlorophenol	decreases activity	1
methyleugenol	decreases expression	1
pirinixic acid	increases activity, increases expression, affects binding	1
nuciferine	increases abundance, increases metabolic processing	1
2,4,5-trichlorophenol	decreases activity	1
enilconazole	decreases expression	1
2-amino-3-methyl-9H-pyrido(2,3-b)indole	increases activity	1
cobaltous chloride	decreases expression	1
2,4,6-trichlorophenol	decreases activity	1
2-amino-3-methylimidazo(4,5-f)quinoline	increases expression	1
2-chlorophenol	decreases activity	1
2,3,4,6-tetrachlorophenol	decreases activity	1
1-hydroxypyrene	increases metabolic processing	1
2,3,5,6-tetrachlorophenate	decreases activity	1
2,3,4,5-tetrachlorophenate	decreases activity	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects cotreatment, decreases expression, affects response to substance	1
4-nonylphenol	increases metabolic processing	1
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	increases expression	1
1-hydroxymethylpyrene	affects cotreatment, increases activity	1
4-octylphenol	increases metabolic processing	1

ChEMBL screening assays

3 unique, capped per target: 3 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1743306	ADMET	Major substrate of human cytosolic sulfotransferase SULT1B1	Casarett and Doull’s Toxicology The Basic Science of Poisons, 7th edition

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety